### International Incidence of Childhood Cancer Volume III

<table>
<thead>
<tr>
<th>Disease Type</th>
<th>USA, Vermont, NH White (1998-2012)</th>
<th>Number of cases</th>
<th>Percentage</th>
<th>Incidence rates per million person-years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-14</td>
<td>5-9</td>
<td>10-14</td>
<td>15-19</td>
</tr>
<tr>
<td><strong>I LEUKAEMIA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Lymphoblastic</td>
<td>3</td>
<td>43</td>
<td>30</td>
<td>36</td>
</tr>
<tr>
<td>b. Acute myeloid</td>
<td>0</td>
<td>33</td>
<td>26</td>
<td>30</td>
</tr>
<tr>
<td>c. MDS &amp; others</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>d. unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>II LYMPHOMA &amp; RELATED</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Hodgkin</td>
<td>2</td>
<td>20</td>
<td>14</td>
<td>12</td>
</tr>
<tr>
<td>b. Non-Hodgkin except BL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Burkitt</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>d. Lymphoreticular</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>e. unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>III CNS NEOPLASMS</strong></td>
<td>4</td>
<td>8</td>
<td>12</td>
<td>22</td>
</tr>
<tr>
<td>a. Ependymoma</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>b. Astrocytoma</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>c. CNs embryonal</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>d. Other gliomas</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>e. Other specified</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>f. Unspecified CNS</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>IV NEUROBLASTOMA</strong></td>
<td>7</td>
<td>7</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>a. (Ganglio)neuroblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Peripheral nervous</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><strong>V RETINOBLASTOMA</strong></td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>a. Nephroblastoma</td>
<td>0</td>
<td>4</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>b. Renal carcinoma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>c. unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>VI RENAL TUMOURS</strong></td>
<td>0</td>
<td>4</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>a. Nephroblastoma</td>
<td>0</td>
<td>4</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>b. Renal carcinoma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>c. unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>VII HEPATIC TUMOURS</strong></td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>a. Hepatoblastoma</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>b. Hepatic carcinoma</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>c. unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>VIII BONE TUMOURS</strong></td>
<td>0</td>
<td>5</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>a. Osteosarcoma</td>
<td>0</td>
<td>4</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>b. Chondrosarcoma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>c. Ewing's related</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>d. Other specified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>e. unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>IX SOFT TISSUE SARCOMA</strong></td>
<td>3</td>
<td>5</td>
<td>12</td>
<td>9</td>
</tr>
<tr>
<td>a. Rhabdomyosarcoma</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>b. Fibrosarcoma</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>c. Kaposi sarcoma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>d. Other specified</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>e. Unspecified</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td><strong>X GERM CELL TUMOURS</strong></td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>a. CNS germ cell</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>b. Other extragonadal</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>c. Gonadal germ cell</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>d. Gonadal carcinoma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>e. Unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>XI CARDIAC &amp; MUSCULAR</strong></td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>a. Adrenocortical</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>b. Thyroid</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>c. Nasopharyngeal</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>d. Melanoma</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>e. Skin carcinoma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>f. Other &amp; unspecified</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><strong>XII OTHER &amp; UNSPECIFIED</strong></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>a. Other specified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>b. Other unspecified</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>23</td>
<td>72</td>
<td>78</td>
<td>89</td>
</tr>
</tbody>
</table>

† includes 29 non-malignant  ‡ includes 1 non-malignant
<table>
<thead>
<tr>
<th>Age Group</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5-9</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>10-14</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>15-19</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

**USA, Vermont, NH (1998-2012)**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5-9</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>10-14</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>15-19</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

**International Incidence of Childhood Cancer Volume III**
http://iicc.iarc.fr/results
<table>
<thead>
<tr>
<th>Age group</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>46 329</td>
<td>42 445</td>
</tr>
<tr>
<td>1-4</td>
<td>191 566</td>
<td>181 181</td>
</tr>
<tr>
<td>Person-years</td>
<td>268 753</td>
<td>254 707</td>
</tr>
<tr>
<td>5-9</td>
<td>306 831</td>
<td>289 224</td>
</tr>
<tr>
<td>10-14</td>
<td>344 384</td>
<td>323 886</td>
</tr>
<tr>
<td>15-19</td>
<td>813 479</td>
<td>767 557</td>
</tr>
<tr>
<td>Total</td>
<td>1 157 863</td>
<td>1 091 443</td>
</tr>
<tr>
<td>Average annual population</td>
<td>54 232</td>
<td>51 170</td>
</tr>
<tr>
<td>0-19</td>
<td>77 191</td>
<td>72 763</td>
</tr>
</tbody>
</table>

Please consult the quality indicators for this registry

International Incidence of Childhood Cancer Volume III [http://iicc.iarc.fr/results](http://iicc.iarc.fr/results)